Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ludwig Kappos

Showing results (1-10 of 603) with videos related to

Pageof 61
Sort By:
Neurological Research and Practice|August 7, 2021
No consensus about consensus?Ludwig Kappos
Neurology|January 11, 2017
Letter Re: Retraction: Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women; Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women: Reply From The AuthorsLudwig Kappos
Neurologic Clinics|January 22, 2005
Interferons in multiple sclerosisLudwig Kappos
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2004
Effect of drugs in secondary disease progression in patients with multiple sclerosisLudwig Kappos
JAMA|July 17, 2012
Evaluating the potential benefit of interferon treatment in multiple sclerosisTobias Derfuss, Ludwig Kappos
International MS Journal|July 29, 2004
Neuroprotection in multiple sclerosis report from the MS Forum 16th Modern Management Workshop, March 2004, Cernobbio, ItalyReinhard Hohlfeld, Ludwig Kappos
Lancet (London, England)|June 5, 2003
Interferons in relapsing remitting multiple sclerosisLudwig Kappos, Jürg Kesselring
Seminars in Immunopathology|December 4, 2009
Progress in understanding inflammatory and autoimmune diseases of the central nervous systemReinhard Hohlfeld, Ludwig Kappos
The Lancet. Neurology|October 4, 2017
PML risk and natalizumab: the elephant in the roomTobias Derfuss, Ludwig Kappos
Journal of Neurology, Neurosurgery, and Psychiatry|April 23, 2013
Predicting PML in natalizumab-treated patients: can we do better?Tobias Derfuss, Ludwig Kappos
Pageof 61

Showing results (1-10 of 603) with videos related to

Sort By:
Pageof 61
Neurological Research and Practice|August 7, 2021
No consensus about consensus?Ludwig Kappos
Neurology|January 11, 2017
Letter Re: Retraction: Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women; Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women: Reply From The AuthorsLudwig Kappos
Neurologic Clinics|January 22, 2005
Interferons in multiple sclerosisLudwig Kappos
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2004
Effect of drugs in secondary disease progression in patients with multiple sclerosisLudwig Kappos
JAMA|July 17, 2012
Evaluating the potential benefit of interferon treatment in multiple sclerosisTobias Derfuss, Ludwig Kappos
International MS Journal|July 29, 2004
Neuroprotection in multiple sclerosis report from the MS Forum 16th Modern Management Workshop, March 2004, Cernobbio, ItalyReinhard Hohlfeld, Ludwig Kappos
Lancet (London, England)|June 5, 2003
Interferons in relapsing remitting multiple sclerosisLudwig Kappos, Jürg Kesselring
Seminars in Immunopathology|December 4, 2009
Progress in understanding inflammatory and autoimmune diseases of the central nervous systemReinhard Hohlfeld, Ludwig Kappos
The Lancet. Neurology|October 4, 2017
PML risk and natalizumab: the elephant in the roomTobias Derfuss, Ludwig Kappos
Journal of Neurology, Neurosurgery, and Psychiatry|April 23, 2013
Predicting PML in natalizumab-treated patients: can we do better?Tobias Derfuss, Ludwig Kappos
Pageof 61